Search research articles
Contact Us
Filters
Showing results (1-10 of 11) with videos related to
Page
of 2
Sort By:
Lancet (London, England)
|
December 5, 2003
The statin wars
Peter Dunselman, Ake Hjalmarson, John Kjekshus, et al.
Clinical Chemistry
|
December 11, 2012
Preanalytical storage does not affect 99th percentile cardiac troponin T concentrations measured with a high-sensitivity assay
Judith M Gillis, Peter Dunselman, Jochen Jarausch, et al.
Journal of Cardiac Failure
|
December 16, 2004
Consistency of the beneficial effect of metoprolol succinate extended release across a wide range dose of angiotensin-converting enzyme inhibitors and digitalis
Jalal K Ghali, Peter Dunselman, Finn Waagstein, et al.
European Journal of Heart Failure
|
October 18, 2005
A statin in the treatment of heart failure? Controlled rosuvastatin multinational study in heart failure (CORONA): study design and baseline characteristics
John Kjekshus, Peter Dunselman, Malin Blideskog, et al.
European Journal of Heart Failure
|
May 27, 2010
Intermittent claudication as a predictor of outcome in patients with ischaemic systolic heart failure: analysis of the Controlled Rosuvastatin Multinational Trial in Heart Failure trial (CORONA)
Sally C Inglis, John J V McMurray, Michael Böhm, et al.
European Journal of Heart Failure
|
January 27, 2009
Predictors of fatal and non-fatal outcomes in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): incremental value of apolipoprotein A-1, high-sensitivity C-reactive peptide and N-terminal pro B-type natriuretic peptide
Hans Wedel, John J V McMurray, Magnus Lindberg, et al.
European Journal of Heart Failure
|
December 22, 2009
An economic evaluation of rosuvastatin treatment in systolic heart failure: evidence from the CORONA trial
Paula K Lorgelly, Andrew H Briggs, Hans Wedel, et al.
Journal of the American College of Cardiology
|
October 2, 2010
Coenzyme Q10, rosuvastatin, and clinical outcomes in heart failure: a pre-specified substudy of CORONA (controlled rosuvastatin multinational study in heart failure)
John J V McMurray, Peter Dunselman, Hans Wedel, et al.
Journal of the American College of Cardiology
|
November 7, 2009
Plasma concentration of amino-terminal pro-brain natriuretic peptide in chronic heart failure: prediction of cardiovascular events and interaction with the effects of rosuvastatin: a report from CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure)
John G F Cleland, John J V McMurray, John Kjekshus, et al.
Circulation
|
November 18, 2009
Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysis
John J V McMurray, John Kjekshus, Lars Gullestad, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 11) with videos related to
Sort By:
Page
of 2
Lancet (London, England)
|
December 5, 2003
The statin wars
Peter Dunselman, Ake Hjalmarson, John Kjekshus, et al.
Clinical Chemistry
|
December 11, 2012
Preanalytical storage does not affect 99th percentile cardiac troponin T concentrations measured with a high-sensitivity assay
Judith M Gillis, Peter Dunselman, Jochen Jarausch, et al.
Journal of Cardiac Failure
|
December 16, 2004
Consistency of the beneficial effect of metoprolol succinate extended release across a wide range dose of angiotensin-converting enzyme inhibitors and digitalis
Jalal K Ghali, Peter Dunselman, Finn Waagstein, et al.
European Journal of Heart Failure
|
October 18, 2005
A statin in the treatment of heart failure? Controlled rosuvastatin multinational study in heart failure (CORONA): study design and baseline characteristics
John Kjekshus, Peter Dunselman, Malin Blideskog, et al.
European Journal of Heart Failure
|
May 27, 2010
Intermittent claudication as a predictor of outcome in patients with ischaemic systolic heart failure: analysis of the Controlled Rosuvastatin Multinational Trial in Heart Failure trial (CORONA)
Sally C Inglis, John J V McMurray, Michael Böhm, et al.
European Journal of Heart Failure
|
January 27, 2009
Predictors of fatal and non-fatal outcomes in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): incremental value of apolipoprotein A-1, high-sensitivity C-reactive peptide and N-terminal pro B-type natriuretic peptide
Hans Wedel, John J V McMurray, Magnus Lindberg, et al.
European Journal of Heart Failure
|
December 22, 2009
An economic evaluation of rosuvastatin treatment in systolic heart failure: evidence from the CORONA trial
Paula K Lorgelly, Andrew H Briggs, Hans Wedel, et al.
Journal of the American College of Cardiology
|
October 2, 2010
Coenzyme Q10, rosuvastatin, and clinical outcomes in heart failure: a pre-specified substudy of CORONA (controlled rosuvastatin multinational study in heart failure)
John J V McMurray, Peter Dunselman, Hans Wedel, et al.
Journal of the American College of Cardiology
|
November 7, 2009
Plasma concentration of amino-terminal pro-brain natriuretic peptide in chronic heart failure: prediction of cardiovascular events and interaction with the effects of rosuvastatin: a report from CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure)
John G F Cleland, John J V McMurray, John Kjekshus, et al.
Circulation
|
November 18, 2009
Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysis
John J V McMurray, John Kjekshus, Lars Gullestad, et al.
Page
of 2